• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".

作者信息

da Silva Filipe Ana, Sreenu Vattipally, Hughes Joseph, Aranday-Cortes Elihu, Irving William L, Foster Graham R, Agarwal Kosh, Rosenberg William, Macdonald Douglas, Richardson Paul, Aldersley Mark A, Wiselka Martin, Ustianowski Andrew, McLauchlan John, Thomson Emma C

机构信息

MRC-University of Glasgow Centre for Virus Research, Glasgow, UK.

Gastrointestinal and Liver Disorders Theme, NIHR Nottingham Biomedical Research Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham, UK.

出版信息

J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12.

DOI:10.1016/j.jhep.2017.11.044
PMID:29339112
Abstract
摘要

相似文献

1
Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".回复：“回复：‘对英格兰国民保健制度针对低收入和中等收入国家罕见丙肝病毒亚型的早期获取项目中直接抗病毒药物治疗的回应’”
J Hepatol. 2018 Apr;68(4):864-866. doi: 10.1016/j.jhep.2017.11.044. Epub 2018 Jan 12.
2
Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries".回复：“对英国国家医疗服务体系（NHS）英格兰早期准入计划中低收入国家罕见丙肝病毒亚型直接抗病毒药物（DAA）治疗的反应”
J Hepatol. 2017 Dec;67(6):1350-1352. doi: 10.1016/j.jhep.2017.07.019. Epub 2017 Aug 5.
3
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries.在英国国家医疗服务体系（NHS）针对来自低收入和中等收入国家的罕见丙型肝炎病毒（HCV）亚型的早期获取项目中对直接抗病毒药物（DAA）疗法的反应。
J Hepatol. 2017 Dec;67(6):1348-1350. doi: 10.1016/j.jhep.2017.06.035. Epub 2017 Aug 5.
4
Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England.在英国，与流行的丙型肝炎病毒亚型感染者相比，地方性丙型肝炎病毒亚型感染者接受直接抗病毒治疗的结果。
J Infect. 2025 Apr;90(4):106465. doi: 10.1016/j.jinf.2025.106465. Epub 2025 Mar 5.
5
Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.资源有限国家中注射吸毒人群丙型肝炎再感染：系统评价和分析。
Int J Environ Res Public Health. 2020 Jul 9;17(14):4951. doi: 10.3390/ijerph17144951.
6
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.改善中低收入国家丙型肝炎治疗的可及性：患者援助计划评估。
Int J Clin Pharm. 2021 Aug;43(4):958-968. doi: 10.1007/s11096-020-01202-1. Epub 2020 Nov 28.
7
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.丙型肝炎感染的直接抗病毒疗法：全球注册、报销及限制情况
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15.
8
Potential market size and impact of hepatitis C treatment in low- and middle-income countries.低收入和中等收入国家丙型肝炎治疗的潜在市场规模及影响
J Viral Hepat. 2016 Jul;23(7):522-34. doi: 10.1111/jvh.12516. Epub 2016 Feb 29.
9
[The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].[直接抗病毒治疗对丙型肝炎病毒相关肝细胞癌诊断的影响]
Nihon Shokakibyo Gakkai Zasshi. 2018;115(2):184-194. doi: 10.11405/nisshoshi.115.184.
10
Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.慢性丙型肝炎感染的再治疗：三个中低收入国家国家治疗方案中的真实世界方案和结果。
Clin Infect Dis. 2022 Feb 11;74(3):513-516. doi: 10.1093/cid/ciab461.

引用本文的文献

1
HCV Diagnosis and Sequencing Using Dried Blood Spots from Patients in Kinshasa (DRC): A Tool to Achieve WHO 2030 Targets.使用金沙萨（刚果民主共和国）患者干血斑进行丙型肝炎病毒诊断和测序：实现世界卫生组织2030年目标的工具
Diagnostics (Basel). 2021 Mar 15;11(3):522. doi: 10.3390/diagnostics11030522.
2
Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.非洲非典型 1 型基因型患者的 SVR 率不理想：对全球消除丙型肝炎的影响。
J Hepatol. 2019 Dec;71(6):1099-1105. doi: 10.1016/j.jhep.2019.07.025. Epub 2019 Aug 7.